Form 4: Neurocrine Biosciences Executive Ingrid Delaet Reports Stock Transactions

Chief Regulatory Officer Ingrid Delaet of Neurocrine Biosciences reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, executed transactions involving the company's common stock on August 13, 2024.
• Delaet exercised non-qualified stock options to acquire 3,043 shares at a price of $103.52 per share.
• Simultaneously, Delaet sold 3,043 shares at a weighted average price of $150.1305 and 4,100 shares at a weighted average price of $150.0813.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 2,507 shares of common stock and 22,049 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the executive's confidence in the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, suggesting they were planned well in advance and not based on immediate insider knowledge.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the existence of a 10b5-1 plan mitigates this concern.

Industry Context

Insider transactions are common in publicly traded companies, and are closely monitored by regulators and investors. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives.
• Rule 10b5-1 trading plans are a common tool used by executives at companies like Amgen, Biogen, and Gilead to manage their stock sales in compliance with insider trading laws.
• The reported transactions are typical for executives managing their personal finances and stock holdings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares involved and the pre-planned nature of the sales.

Key Dates